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Abstract
Background: Radioiodine treatment of hyperthyroidism in Graves’ disease patients may cause or aggravate the course of ophthalmopathy 
(GO). We evaluated the activity and severity of ophthalmopathy in patients who acquired GO following radioiodine therapy.
Material and methods: Between 2003 and 2005, 763 Graves’ disease patients (50.9% of the total number of 1,500 patients referred to our 
Department) were treated with radioiodine 131-I. This treatment was only offered to patients with NOSPECS score < 3 and CAS < 3. 
Following their radioiodine treatment, in 39 patients (5.1% of all Graves’ disease patients), mean age 53.9 ± 11.6 years, onset of GO was 
observed within 12 months of post-treatment follow-up.  
Results: In 39 patients who developed GO after 131-I treatment, median values of hTRAb and NOSPECS score were 15.4 U/L (IQR = 22.9) 
and 5.0 points (max = 8.0; min = 2.0), respectively, at the time of their GO onset. Patients were qualified for methylprednisolone pulse 
therapy (8.0 g) and subsequent radiotherapy (20 Gy). Median concentration of hTRAb and NOSPECS score at one, six and 12 months 
post-GO therapy were: 10.0 U/L (IQR = 21.6) and 4.0 (max = 6.0; min = 1.0); 7.5 U/L (IQR = 1.1) and 3.0 (max = 10.0; min = 0.0); 2.8 U/L 
(IQR = 8.3) and 3.0 (max = 6.0; min = 0.0), respectively. A positive association between hTRAb and NOSPECS score was observed over 
the control period. IL-6 and IL-2 concentration prior to and one month after treatment remained elevated. 
Conclusions: Since 5% of our Graves’ disease patients developed severe GO following radioiodine treatment, an association between 
radioiodine therapy and severe ophthalmopathy cannot be excluded. IL-6 and IL-2 concentrations remained elevated after glucocorticoid 
therapy. (Pol J Endocrinol 2011; 62 (3): 214–219)
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Streszczenie
Wstęp: Leczenie radiojodem nadczynności tarczycy u pacjentów z chorobą Gravesa może spowodować pojawienie się oftalmopatii (GO) 
de novo lub jej zaostrzenie.  W pracy oceniono aktywność i stopień zaawansowania GO u pacjentów po leczeniu radiojodem. 
Materiał i metody: W latach 2003–2005763 pacjentów z chorobą Gravesa (50,9% z 1500 pacjentów skierowanych do naszego ambulato-
rium) leczono radiojodem 131-I. Leczenie proponowano pacjentom z NOSPECS < 3 i CAS < 3 punkty. U 39 pacjentów (5,1% pacjentów 
z chorobą Gravesa), średnia wieku 53,9 ± 11,6 roku, obserwowano rozwój oftalmopatii w ciągu roku po leczeniu. 
Wyniki: U 39 pacjentów z GO po leczeniu 131-I mediany stężenia hTRAb i NOSPECS wynosiły na początku choroby 15,4 U/L (IQR = 22,9) 
i 5 punktów (max = 8,0; min = 2,0) odpowiednio. Pacjentów zakwalifikowano do leczenia pulsami metylprednizolonu (8,0 g) i uzupeł-
niającej radioterapii (20 Gy). Mediany stężenia hTRAb i NOSPECS po 1, 6 i 12 miesiącach wynosiły 10,0 U/L (IQR = 21,6) i 4,0 (max = 6,0; 
min = 1,0); 7,5 U/L (IQR = 12,1) i 3,0 (max = 10,0; min = 0,0); 2,8 U/L (IQR = 8,3) i 3,0 (max = 6,0; min = 0,0), odpowiednio. W czasie 
obserwacji stwierdzono dodatnią zależność pomiędzy stężeniem hTRAb i NOSPECS. Odnotowano podwyższone stężenia IL-6 i IL-2 
przed leczeniem i 1 miesiąc po leczeniu glikokortykoidami.  
Wnioski: Ponieważ 5% badanych pacjentów z chorobą Gravesa zachorowało na ciężką GO po leczeniu radiojodem, nie można wyklu-
czyć związku pomiędzy leczeniem 131-I a następowym rozwojem oftalmopatii. Stężenia IL-6 i IL-2 pozostały podwyższone po leczeniu 
glikokortykoidami. (Endokrynol Pol 2011; 62 (3): 214–219)
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Graves’ ophthalmopathy (GO) is clinically associated 
with autoimmune thyroid disease and the production 
of autoantibodies to thyroidal antigens. In particular, 
autoantibodies to thyroid stimulating hormone receptor 
(TSH-R) may be involved in the pathogenesis of GO, 
as TSH-R is expressed in retro-orbital fibroblasts and 
fat cells [1]. The course of GO appears to be affected 
by treatment of thyrotoxicosis and there is growing 
evidence that the application of radioiodine therapy 
may enhance the  risk of GO occurrence, or its severity. 
In Bartalena et al. randomised study [2] which con-
firmed the results of an earlier randomised trial by Tall-
stedt et al. [3], radioiodine treatment of hyperthyroidism 
was found to cause or aggravate the course of GO in 15% 
of patients studied, while only 3% of patients treated 
with methimazole developed GO. Although such con-
sequences of radioiodine treatment are recognised, the 
mechanisms by which GO is promoted are not well un-
derstood. The rise of antibody titers observed following 
radioiodine application is probably due to the release of 
antigens from radiation-damaged thyrocytes. The rapid 
development of hypothyroidism after 131-I treatment 
implicates TSH-R activation as an important factor in 
the evolution of GO [4, 5].
In our retrospective analysis, we evaluated the acti-
vity and severity of ophthalmopathy in patients who 
acquired GO following their radioiodine therapy. 
Material and methods
At our Department of Endocrinology between 2003 
and 2005, 763 Graves’ disease patients (50.9% of the 
total number of 1,500 patients referred) underwent 
radioiodine 131-I therapy. Following their radioiodine 
treatment, in 31 females and eight males (i.e. 5.1% of all 
Graves’ patients), mean age 53.9 ± 11.6 years, onset of 
GO was observed within 12 months of post-treatment 
follow-up (mean time of onset: 23.4 ± 22.8 weeks).
All patients received methimazole prior to radio-
iodine for 3-12 months at out-patient facilities other 
than our Department. Methimazole was discontinued 
seven days before radioiodine therapy. Over the period 
of 6-8 weeks following 131-I administration, control of 
hyperthyroidism was achieved with a b-blocker (pro-
pranolol). 131-I therapy was only offered to patients 
with NOSPECS (No signs or symptoms; Only signs; 
Soft tissue involvement; Proptosis; Extraocular muscle 
involvement; Corneal involvement; Sight loss) total 
eye score (TES) < 3 points and clinical activity score 
(CAS) < 3 points [6, 7]. Prior to their 131-I treatment, 
mean TSH concentration in this group was 0.24 ± 0.58 
μU/ml and mean 24-hour 131-I uptake was 54.0 ± 14.6%. 
The mean activity of 131-I applied was 496 ± 141 MBq. 
Of patients in the group referred to our Department 
due to eye problems, 82% were hypothyroid. Their 
median level of maximum TSH after 131-I treatment 
was 6.2 μU/ml (IQR = 13.8). Patients were rendered 
euthyroid with appropriate doses of L-thyroxine at the 
time of their GO treatment. Throughout the 12 month 
follow-up, all these patients were maintained euthyroid. 
Patients were qualified for methylprednisolone pulse 
therapy (2.0 g per week for four consecutive weeks) 
and subsequent radiotherapy (20 Gy).
The severity and activity of GO were evaluated ac-
cording to NOSPECS classification, presented as TES 
and CAS prior to and one, six, and 12 months after 
131-I treatment.
For laboratory measurements, the following methods 
were used: TSH — ECLIA (Roche), hTRAb (thyrotropin 
receptor antibodies) — TRAK human RRA (Brahms), 
IL-2 (interleukin 2) — OPTEIA (Pharmingen), IL-6 
(interleukin 6) — ELISA KIT II BD (Bioscenses). Basic 
statistics (mean ± SD, median, IQR), U-Mann-Whitney 
test, Wilcoxon test, Spearman’s rank correlation test, 
Shapiro-Wilk test or Fisher’s test were applied in our 
statistical analysis, all with the use of a StatSoft STATIS-
TICA version 9.0 package. 
Results
In patients who developed GO after 131-I treatment, 
median values of hTRAb and NOSPECS were 15.4 U/L 
(IQR = 22.9) and 5.0 points (max = 8.0; min = 2.0), 
respectively, at the time of their GO onset. Patients re-
ported for control one, six and 12 months post-therapy. 
Median concentration of hTRAb and NOSPECS score 
at one, six and 12 months were: 10.0 U/L (IQR = 21.6) 
and 4.0 (max = 6.0; min = 1.0); 7.5 U/L (IQR = 12.1) and 
3.0 (max = 10.0; min = 0.0); 2.8 U/L (IQR = 8.3) and 3.0 
(max = 6.0; min = 0.0), respectively. 
In about 56% of the total number of patients (22/39), 
CAS exceeded 4 points, while about 80% of these 
patients developed moderately severe or severe GO. 
The relation between TES and CAS was found to be 
significant, based on the Fisher’s test (p < 0.05) (Table I). 
A positive correlation between CAS and NOSPECS 
(TES) prior to and one month after GO therapy was 
found (correlation coefficient r = 0.71 and r = 0.68, 
respectively, p < 0.05). 
The results of GO therapy after one month post-I-131 
treatment are illustrated by differences in CAS over 
this period. The difference between median values of 
CAS (4.0; max = 7.0; min = 2.0) prior to and one month 
after therapy (2.0; max = 5.0; min = 0.0), illustrated in 
Figure 1, was found to be statistically significant 
(p < 0.05, Wilcoxon paired data test). 
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Differences in median hTRAb levels prior to treat-
ment and after consecutive time intervals, shown 
in Figure 2, were found to be statistically significant 
(p < 0.05, Wilcoxon paired data test). No correlations 
were observed between hTRAb and CAS, TES or inter-
leukin levels. A positive correlation between hTRAb le-
vels prior to and one, six, and 12 months after treatment 
was found (correlation coefficient r = 0.79, r = 0.76, and 
r = 0.57, respectively, p < 0.05).
Differences in median TES values prior to treat-
ment and after consecutive time intervals, shown 
in Figure 3, were found to be statistically significant 
(p < 0.05, Wilcoxon paired data test). A positive cor-
relation between TES level prior to and one, six, and 
12 months after treatment was found (correlation 
Table I. Patient characteristics in different groups of 
disease activity (CAS) prior to glucocorticoid therapy 
(n = 39). The relation between TES and CAS is statistically 
significant (Fisher’s test, p < 0.05)
Tabela I. Charakterystyka pacjentów w zależności od 
aktywności choroby (CAS) przed leczeniem glikokortykoidami 
(n = 39). Stwierdzono znamienną zależność między TES i CAS 
(test Fishera, p < 0.05)
TES CAS < 4 pts  
n = 17 patients
CAS ≥ 4 pts  










Figure 1. Clinical Activity Score (CAS) prior to and one month 
after GO therapy
Rycina 1. Indeks aktywności choroby przed leczeniem i 1 miesiąc 
po leczeniu GO
Figure 2. hTRAb levels over 12 months after GO therapy. 
Differences between median hTRAb levels over consecutive time 
intervals are statistically significant (Wilcoxon test, p < 0.05)
Rycina 2. Stężenie hTRAb w okresie 12 miesięcy po leczeniu 
GO. Stwierdzono znamienne statystycznie różnice pomiędzy 
medianami stężeń hTRAb w kolejnych przedziałach czasowych 
(test Wilcoxona, p< 0.05)
Figure 3. Total Eye Score (TES) over 12 months after GO therapy. 
Differences between median TES values over consecutive time 
intervals are statistically significant (Wilcoxon test,  p < 0.05)
Rycina 3. Indeks oftalmopatii (TES) w okresie 12 miesięcy po 
leczeniu GO. Stwierdzono znamienne statystycznie różnice 
pomiędzy medianami TES w kolejnych przedziałach czasowych 
(test Wilcoxona, p < 0.05)
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coefficient r = 0.81, r = 0.57, and r = 0.69 respectively, 
p < 0.05).
Over the 12 month period, a decrease of hTRAb 
concentration and a decrease of TES were observed, 
although this association was not found to be statisti-
cally significant. 
The prevalence of hTRAb at 12 months after ster-
oid therapy was also studied. Some 93% of patients 
were hTRAb-positive before treatment. At 12 months 
following GO therapy, 55% of patients still remained 
hTRAb-positive while the TES of most patients had 
significantly improved, as illustrated in Figure 3. 
On dividing patients into mild and severe GO based 
on values of CAS (CAS < 4 and CAS ≥ 4, respectively) 
we found that the difference between median levels of 
hTRAb was statistically significant 12 months after GO 
therapy (U-Mann-Whitney test, p < 0.05). The differ-
ences in median levels of hTRAb prior to, and one and 
six months after therapy were not significant. We also 
noted the difference in distributions of hTRAb values 
between these groups (Figure 4).
On dividing patients into mild and severe GO based 
on TES (TES < 5 and TES ≥ 5, respectively), we observed 
similar features. The difference between median levels 
of hTRAb prior to and 12 months after GO therapy was 
statistically significant (U-Mann-Whitney test, p < 0.05), 
there was also a difference in hTRAb distribution in each 
group (Figure 5). 
Prior to treatment, the distribution of IL-2 and IL-6 
values in our group of patients was quite skewed (with 
low minima of 2.6 pg/ml and 3.5 pg/ml, respectively 
and very high maxima of 365.8 pg/ml and 418.0 pg/ml, 
respectively). The median values were close to the upper 
normal range: IL-2 = 18.4 pg/ml (normal range 0–20.8 
pg/ml) and IL-6 = 10.6 pg/ml (normal range 0.7–12.1 
pg/ml). In 50% of the patients, IL-2 and IL-6 concentra-
tions prior to and one month post-treatment remained 
elevated and did not correlate with hTRAb concentra-
tions or with NOSPECS values. The decrease of IL-2 
concentration correlated with the decrease of IL-6 
concentration over the one month period (correlation 
coefficient r = 0.52, p < 0.05). The IL-2 concentration 
prior to GO treatment correlated with maximum TSH 
concentrations after I-131 treatment (correlation coef-
ficient r = 0.50, p < 0.05). 
In our group of GO patients, we observed a high per-
centage of severe (grade 3) upper lid retraction (24%), 
soft tissue oedema (21%) and muscle impairment (30%) 
following their radioiodine treatment. Six months later, 
we considered our therapy to be effective, as worsening 
of GO was observed in only one patient. 
Discussion
In the 1990s, two randomised, controlled trials [2, 3] de-
monstrated that radioiodine therapy is associated with 
a small but definite risk of GO progression. Anti-thyroid 
drug treatment (ATD) and thyroidectomy are associated 
with a gradual decrease in hTRAb concentration, while 
hTRAb levels seem to increase over a one year period 
after I-131 administration [8, 9]. Laurberg et al. [8] meas-
ured hTRAb in serum before and five years after the 
Figure 4. hTRAb levels 12 months after GO therapy in patients 
with mild (CAS < 4) and severe (CAS ≥ 4) ophthalmopathy
Rycina 4. Stężenia hTRAb 12 miesięcy po leczeniu GO w grupie 
pacjentów z łagodną (CAS < 4) i ciężką (CAS ≥ 4) oftalmopatią
Figure 5. hTRAb levels 12 months after GO therapy in patients 
with mild (TES < 5 ) and severe (TES ≥ 5) ophthalmopathy 
Rycina 5. Stężenia hTRAb 12 miesięcy po leczeniu GO w grupie 
pacjentów z łagodną (TES < 5) i ciężką (TES ≥ 5) oftalmopatią
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initiation of medical therapy, surgery or radioiodine in 
Graves’ patients with hyperthyroidism [8]. Radioiodine 
therapy led to worsening of autoimmunity against the 
TSH receptor. The number of patients entering remis-
sion with disappearance of serum hTRAb during five 
years of follow-up was considerably lower than after 
other types of therapy [8]. 
It seems that peak incidence of GO occurs six months 
after 131-I administration, but GO may develop at 
any time (1-24 months) after radioiodine treatment, as 
shown by Acharaya et al. [10] in their analysis of ran-
domised control trials. In our group of patients, onset 
of GO was observed most frequently within 12 months 
post-131-I therapy. However in some patients, the first 
symptoms of GO were not observed until after two 
years, which may be explained by the extended period 
of hTRAb elevation in patients treated with 131-I [8]. 
It has been suggested that in patients with active 
GO, anti-thyroid drugs should be the treatment of 
choice for hyperthyroidism and GO should be treated 
promptly [11]. However, Menconi et al. [12] showed in 
a randomised study that total thyroid ablation (near 
total thyroidectomy followed by radioiodine therapy) 
gave a better outcome of GO immunosuppressive treat-
ment than near–total thyroidectomy alone. Therefore, 
it has been recently proposed that patients with active 
GO be treated early with ablative therapy for their 
hyperthyroidism, with concomitant GO therapy [13]. 
EUGOGO has no clear-cut opinion on treating hyper-
thyroidism in GO, i.e. by anti-thyroid medication or by 
more aggressive ablation [14]. 
A recent systematic review by Acharaya et al. [10] 
and the study by the Swedish Thyroid Study Group [15] 
published several years after the randomised controlled 
trials by Tallstedt and Bartalena [2, 3] confirm  that I-131 
therapy can cause exacerbation of GO. Other established 
risk factors of GO worsening after radioiodine are smok-
ing [15, 16], severity of hyperthyroidism expressed by 
pre-treatment serum T3 level of ≥ 5 nmol/l [3] or un-
treated hypothyroidism following 131-I treatment [17]. 
Of all patients referred to our Department due to eye 
problems, 82% were hypothyroid, some of them with 
TSH levels as high as 91.7 μU/ml. Since normalisation of 
thyroid function is considered to be essential in reducing 
severity and improving the outcome of GO treatment 
[18, 19], our patients remained euthyroid over the one 
year follow-up period. 
In the randomised controlled trials analysed by Ach-
araya et al. [10], no correlation was observed between 
hTRAb levels and the progression of ophthalmopathy. 
In our study, no correlations were observed between 
hTRAb and CAS, TES or interleukin levels. However, 
over the 12 month period of follow-up, a decrease of 
hTRAb concentration and a decrease of TES were ob-
served, although this association was not statistically 
significant. According to the study by Eckstein et al. 
[20], a high hTRAb level represents an independent 
risk factor for developing more severe GO, and should 
be considered a risk factor for GO progression after 
radioiodine therapy. 
Radioiodine is more likely to induce progression of 
pre-existing GO than cause de novo occurrence of this 
complication [2]. A small but significant proportion of 
patients (5%) experience severe GO [18]. Indeed, in our 
study, onset of GO was observed in 5.1% of patients with 
Graves’ disease treated with radioiodine 131-I, and 80% 
of these patients were diagnosed with moderately se-
vere or severe GO with a pre-treatment CAS value of  ≥ 4 
points. In several retrospective studies and randomised 
trials, the risk of GO development or progression after 
hyperthyroidism therapy with anti-thyroid drug treat-
ment or surgery has been compared to radioiodine treat-
ment [2, 3, 21, 22]. The risk of GO after 131-I treatment 
varied between 15% and 39%, compared to the risk of 
GO after ATD (anti-thyroid drugs) of 3- 21% and after 
surgery, where the risk was 16% [21]. Although the 
absolute risk is fairly small, it cannot be ignored [10].
Worsening of pre-existing thyroid-associated oph-
thalmopathy after radioiodine therapy can be prevented 
by the administration of glucocorticoids [2, 22, 23]. This 
treatment can also ameliorate pre-existing GO [2, 22, 23] 
and should be standard practice [10]. 
In patients without clinical signs of pre-existing GO, 
prednisolone prophylaxis may also be beneficial [9, 22], 
although its routine use following 131-I has yet to be 
justified [10]. 
To establish whether cytokine levels correlate with 
GO activity and severity, we measured IL-2 and IL-6 
concentrations in our patients prior to and one month 
after treatment. In our study, the median concentrations 
of IL-2 and IL-6 in euthyroid patients with moderate to 
severe GO and CAS ≥ 4 points prior to treatment were 
around upper normal ranges. 
Wakelkamp et al. [24] found IL-6 levels and sIL-2R 
to be significantly elevated in moderately severe GO 
euthyroid patients treated with anti-thyroid drugs, com-
pared to healthy controls. In their study, the increase of 
pro-inflammatory interleukins was attributed to active 
eye disease rather than to thyroid autoimmune disease 
or related to the thyroid status. The cytokine levels 
did not correlate with GO activity (CAS) or severity 
(NOSPECS). This is in agreement with our study, where 
in some 50% of patients IL-2 and IL-6 concentrations 
prior to and one month post-treatment remained el-
evated and did not correlate with hTRAb levels or with 
NOSPECS values. Łącka et al. [25] found a significant se-
rum IL-6 increase in euthyroid GO patients with CAS ≥ 4 
points, compared to healthy controls. Two weeks after 
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glucocorticoid therapy, serum IL-6 had decreased in 
most of their patients. On the other hand, Myśliwiec 
et al. [26] found increased serum IL-6 levels in patients 
with GO compared to controls, and no change after 
glucocorticoid treatment. 
As far as we know, sIL-2R rather than IL-2 serum 
concentrations were studied on active GO patients, as 
circulating levels of sIL-2R appear to correlate with the 
activity of several autoimmune diseases. The levels of 
IL-2, IL-6, sIL-2R, and sIL-6R have been found to be 
significantly higher in patients with active GO than in 
control patients [27–29]. The levels of sIL-2R and sIL-6R 
decreased after glucocorticoid treatment [27] and did 
not correlate with hTRAb levels [28, 29]. Similarly, in 
our study, IL-2 concentrations did not correlate with 
hTRAb levels. In vitro studies of orbital tissue have also 
demonstrated higher mRNA levels of proinflammatory 
IL-6 and IL-2 in active GO, compared to inactive GO 
orbital tissues [30]. 
It appears that while the role of cytokine is evident 
in the autoimmune process which occurs in the orbit 
as GO develops, there is as yet no consensus as to the 
best serum cytokine in terms of indicating the severity 
of GO or acting as a predictor of treatment efficacy or 
an indicator of the best treatment strategy. 
Conclusions
Since 5% of our Graves’ disease patients developed 
severe GO following radioiodine treatment, an associa-
tion between radioiodine therapy and severe ophthal-
mopathy cannot be excluded. Preventive administration 
of glucocorticoids should be recommended in patients 
with Graves’ disease, even with mild ophthalmopathy, 
when planning radioiodine therapy. IL-6 and IL-2 
concentrations remained elevated after glucocorticoid 
therapy. 
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